<?xml version='1.0' encoding='utf-8'?>
<document id="12397887"><sentence text="A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir."><entity charOffset="49-60" id="DDI-PubMed.12397887.s1.e0" text="venlafaxine" /><entity charOffset="65-74" id="DDI-PubMed.12397887.s1.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12397887.s1.e0" e2="DDI-PubMed.12397887.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s1.e0" e2="DDI-PubMed.12397887.s1.e1" /></sentence><sentence text="Depression is a common occurrence in the human immunodeficiency virus (HIV)-infected population" /><sentence text=" Complications in treating depressed HIV-infected individuals include the use of multiple medications, additive side effects, and potentially significant drug-drug interactions" /><sentence text=" Based on the pharmacologic characteristics of venlafaxine and indinavir, we hypothesized that significant pharmacokinetic drug-drug interactions would not occur when these drugs where taken concurrently"><entity charOffset="47-58" id="DDI-PubMed.12397887.s4.e0" text="venlafaxine" /><entity charOffset="63-72" id="DDI-PubMed.12397887.s4.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12397887.s4.e0" e2="DDI-PubMed.12397887.s4.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s4.e0" e2="DDI-PubMed.12397887.s4.e1" /></sentence><sentence text=" Nine healthy adult subjects were given a single 800 mg oral dose of indinavir and serial blood samples were collected for measurement of plasma drug concentrations"><entity charOffset="69-78" id="DDI-PubMed.12397887.s5.e0" text="indinavir" /></sentence><sentence text=" Over the next 9 days, venlafaxine was administered at a dosage of 50 mg every 8 hours following a brief titration"><entity charOffset="23-34" id="DDI-PubMed.12397887.s6.e0" text="venlafaxine" /></sentence><sentence text=" A venlafaxine trough plasma concentration and serial concentrations following venlafaxine administration were obtained on day 10"><entity charOffset="3-14" id="DDI-PubMed.12397887.s7.e0" text="venlafaxine" /><entity charOffset="79-90" id="DDI-PubMed.12397887.s7.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.12397887.s7.e0" e2="DDI-PubMed.12397887.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s7.e0" e2="DDI-PubMed.12397887.s7.e1" /></sentence><sentence text=" On day 11, venlafaxine and indinavir were administered together and serial blood sampling was repeated"><entity charOffset="12-23" id="DDI-PubMed.12397887.s8.e0" text="venlafaxine" /><entity charOffset="28-37" id="DDI-PubMed.12397887.s8.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12397887.s8.e0" e2="DDI-PubMed.12397887.s8.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s8.e0" e2="DDI-PubMed.12397887.s8.e1" /></sentence><sentence text=" Indinavir had no effect on venlafaxine plasma concentrations but resulted in a 7% decrease in plasma concentrations of O-desmethyl-venlafaxine (ODV)(P = 0"><entity charOffset="1-10" id="DDI-PubMed.12397887.s9.e0" text="Indinavir" /><entity charOffset="28-39" id="DDI-PubMed.12397887.s9.e1" text="venlafaxine" /><entity charOffset="120-143" id="DDI-PubMed.12397887.s9.e2" text="O-desmethyl-venlafaxine" /><pair ddi="false" e1="DDI-PubMed.12397887.s9.e0" e2="DDI-PubMed.12397887.s9.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s9.e0" e2="DDI-PubMed.12397887.s9.e1" /><pair ddi="false" e1="DDI-PubMed.12397887.s9.e0" e2="DDI-PubMed.12397887.s9.e2" /><pair ddi="false" e1="DDI-PubMed.12397887.s9.e1" e2="DDI-PubMed.12397887.s9.e1" /><pair ddi="false" e1="DDI-PubMed.12397887.s9.e1" e2="DDI-PubMed.12397887.s9.e2" /></sentence><sentence text="028)" /><sentence text=" This effect is unlikely to be clinically significant" /><sentence text=" Venlafaxine coadministration resulted in a 28% decrease in the area under the concentration time curve (AUC) of plasma indinavir (P = 0"><entity charOffset="1-12" id="DDI-PubMed.12397887.s12.e0" text="Venlafaxine" /></sentence><sentence text="016) and a 36% decrease in its maximum plasma concentration (Cmax; P = 0" /><sentence text="038)" /><sentence text=" As the plasma concentration of protease inhibitors is a critical factor in maintaining efficacy and minimizing the potential for viral resistance, the decrease in both AUC and Cmax of indinavir from coadministration of venlafaxine is of concern"><entity charOffset="185-194" id="DDI-PubMed.12397887.s15.e0" text="indinavir" /><entity charOffset="220-231" id="DDI-PubMed.12397887.s15.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.12397887.s15.e0" e2="DDI-PubMed.12397887.s15.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s15.e0" e2="DDI-PubMed.12397887.s15.e1" /></sentence><sentence text=" The clinical significance of these results obtained from a small number of healthy volunteers is unknown" /><sentence text=" Further studies are needed to substantiate or refute this apparent drug-drug interaction" /><sentence text=" Until such time, venlafaxine should be used cautiously in patients receiving indinavir"><entity charOffset="18-29" id="DDI-PubMed.12397887.s18.e0" text="venlafaxine" /><entity charOffset="78-87" id="DDI-PubMed.12397887.s18.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.12397887.s18.e0" e2="DDI-PubMed.12397887.s18.e0" /><pair ddi="false" e1="DDI-PubMed.12397887.s18.e0" e2="DDI-PubMed.12397887.s18.e1" /></sentence><sentence text="" /></document>